Home - Invent VTE

Fostering International VTE Research Collaboration

INVENT-VTE seeks to improve the care of patients affected by venous thromboembolism (VTE) around the world through the design, development, conduct and promotion of high-quality clinical research into the causes, prevention, diagnosis and optimal management of VTE.

Countries Involved

Funding Opportunities

Endorsed Studies

Keywords:

Title (Acronym):

Title (Full):

Registration:

Sponsor(s):

Design:

Status:

Email:

Lead Developer:

Current Participants:

Lead Investigators:

TILE

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Sponsor:

Sunnybrook Health Sciences Centre

Toronto, Canada

Current Participant(s):

Canada, France,

Status:

Seeking sites and collaborators

Lead Network:

CanVECTOR

PLATO-VTE

Platelet mRNA profiling to detect occult cancer in unprovoked venous thromboembolism

Sponsor:

Academic Medical Center

Amsterdam, the Netherlands

Current Participant(s):

Belgium, Canada, Germany, Italy, Spain, The Netherlands, USA,

Status:

Recruitment Completed
Analyzing Results

Lead Network:

DTN

RIVASVT-100

Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study

Sponsor:

Università degli Studi dell'Insubria

Varese, Italy

Current Participant(s):

Canada, France, Germany, Italy,

Status:

Recruited started 2015
Seeking sites and collaborators

Lead Network:

TRIP

VERDICT

Venous thromboembolism in renally impaired patients and direct oral anticoagulants

Sponsor:

Centre Hospitalier Universitaire de Saint Etienne

Saint Etienne, France

Current Participant(s):

Canada, France, Serbia, Spain, Switzerland,

Status:

Seeking sites and collaborators

Lead Network:

INNOVTE

RENOVE

REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial

Sponsor:

Brest University Hospital

Brest, France

Current Participant(s):

France,

Status:

Seeking sites and collaborators

Lead Network:

INNOVTE

SAVER/SPIRIT

StAtins for Venous Event Reduction in Patients With Venous Thromboembolism: A Pilot Study Assessing Feasibility of an RCT to Evaluate if Generic Rosuvastatin Reduces the Risk of Recurrent VTE in Patients With Symptomatic Major VTE

Sponsor:

OHRI (Ottawa Hospital Research Institute)

Current Participant(s):

Canada, Norway,

Status:

Pilot trial recruited in Canada and Norway
Recruitment Completed
Secured Funding to Begin Full Trial

Lead Network:

CanVECTOR

THEIA

Advanced diagnostic management of suspected recurrent ipsilateral deep vein thrombosis of the leg with magnetic resonance direct thrombus imaging

Sponsor:

Leiden University Medical Center

Current Participant(s):

Canada, Norway, Sweden, The Netherlands,

Status:

Recruitment Completed
Late Breaking Abstracts - ISTH 2019 Congress

Lead Network:

DTN

HIGHLOW

Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses

Current Participant(s):

Belgium, Canada, France, Ireland, Norway, The Netherlands, USA,

Status:

Recruiting
Seeking sites and collaborators

Lead Network:

DTN

ALIFE2

Anticoagulants for living fetuses in women with recurrent miscarriage and inherited thrombophilia

Current Participant(s):

Belgium, Canada, The Netherlands, USA,

Status:

Recruiting
Seeking sites and collaborators

Lead Network:

DTN

PEITHO-III

A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism

Sponsor:

Hopital Européen Georges Pompidou, Assistance Publique Hopitaux de Paris, Université Paris Descartes

Current Participant(s):

Belgium, Canada, France, Germany, Italy, Poland, Romania, Spain, The Netherlands,

Status:

Seeking sites and collaborators

Lead Network:

INNOVTE

Pilot PARTUM

Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Sponsor:

University of Calgary

Current Participant(s):

Canada, The Netherlands, USA,

Status:

Planning to begin recruitment in January 2020

Lead Network:

CanVECTOR

ADJUST-DVT

Age-adjusted d-dimer cutoff levels to rule out deep vein thrombosis

Sponsor:

University Hospital

Geneva, Switzerland

Current Participant(s):

Canada, Switzerland,

Status:

Recruiting
Seeking sites & collaborators

Lead Network:

INNOVTE

REDUCE

Management of recurrent venous thromboembolism during anticoagulant treatment in cancer patients - a prospective cohort study

Sponsor:

Amsterdam University Medical Center

Amsterdam, the Netherlands

Current Participant(s):

Italy, The Netherlands,

Lead Network:

DTN

Rhea

Optimizing diagnosis of splanchnic vein thrombosis with MR direct thrombus imaging

Sponsor:

The Netherlands: Dutch Thrombosis Network (Leiden University Medical Center, Leiden; Erasmus Medisch Centrum, Rotterdam)
Italy: Thrombosis Research Italian Partnership (Varese University Hospital, Varese)

Current Participant(s):

Italy, The Netherlands,

Lead Network:

DTN

COBRRA

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Sponsor:

OHRI (Ottawa Hospital Research Institute)

Current Participant(s):

Australia & New Zealand, Canada,

Lead Network:

CanVECTOR

Professional Membership

ELIGIBLE APPLICANTS ARE INVITED TO JOIN

Call for COVID-19 / VTE Related Research Projects for Network Endorsement

Statement from the INVENT Network Chair & Vice-Chair

Interested in Becoming a National VTE Research Network

Fostering International VTE Research Collaboration

Endorsed Studies

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Sponsor:

Current Participant(s):

Status:

Lead Network:

Platelet mRNA profiling to detect occult cancer in unprovoked venous thromboembolism

Sponsor:

Current Participant(s):

Status:

Lead Network:

Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study

Sponsor:

Current Participant(s):

Status:

Lead Network:

Venous thromboembolism in renally impaired patients and direct oral anticoagulants

Sponsor:

Current Participant(s):

Status:

Lead Network:

REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial

Sponsor:

Current Participant(s):

Status:

Lead Network:

StAtins for Venous Event Reduction in Patients With Venous Thromboembolism: A Pilot Study Assessing Feasibility of an RCT to Evaluate if Generic Rosuvastatin Reduces the Risk of Recurrent VTE in Patients With Symptomatic Major VTE

Sponsor:

Current Participant(s):

Status:

Lead Network:

Advanced diagnostic management of suspected recurrent ipsilateral deep vein thrombosis of the leg with magnetic resonance direct thrombus imaging

Sponsor:

Current Participant(s):

Status:

Lead Network:

Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses

Current Participant(s):

Status:

Lead Network:

Anticoagulants for living fetuses in women with recurrent miscarriage and inherited thrombophilia

Current Participant(s):

Status:

Lead Network:

A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism

Sponsor:

Current Participant(s):

Status:

Lead Network:

Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Sponsor:

Current Participant(s):

Status:

Lead Network:

Age-adjusted d-dimer cutoff levels to rule out deep vein thrombosis

Sponsor:

Current Participant(s):

Status:

Lead Network:

Management of recurrent venous thromboembolism during anticoagulant treatment in cancer patients - a prospective cohort study

Sponsor:

Current Participant(s):

Lead Network:

Optimizing diagnosis of splanchnic vein thrombosis with MR direct thrombus imaging

Sponsor:

Current Participant(s):

Lead Network:

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Sponsor:

Current Participant(s):

Lead Network:

Subscribe